Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Chu

Showing results (51-60 of 211) with videos related to

Pageof 22
Sort By:
Clinical Colorectal Cancer|October 20, 2007
The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancerErin Grothey, Edward Chu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
The role of thymidylate synthase as a molecular biomarkerAntontello DiPaolo, Edward Chu
Clinical Colorectal Cancer|December 17, 2002
Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instabilityLori Johnson, Edward Chu
Clinical Colorectal Cancer|June 15, 2015
Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon CancerAmy Soni, Edward Chu
Clinical Colorectal Cancer|November 27, 2002
Thymidylate Synthase Pharmacogenetics in Colorectal CancerM Sitki Copur, Edward Chu
The New England Journal of Medicine|January 19, 2007
Expanding priorities--confronting chronic disease in countries with low incomeGerard F Anderson, Edward Chu
Oncology (Williston Park, N.Y.)|June 2, 2006
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancersEverett E Vokes, Edward Chu
Oncology (Williston Park, N.Y.)|October 19, 2013
Personalized medicine in the adjuvant chemotherapy of stage II colon cancer--are we there yet?James J Lee, Edward Chu
Clinical Colorectal Cancer|March 1, 2017
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102)James J Lee, Edward Chu
Silence|January 21, 2011
Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitorsJohn C Schmitz, Edward Chu
Pageof 22

Showing results (51-60 of 211) with videos related to

Sort By:
Pageof 22
Clinical Colorectal Cancer|October 20, 2007
The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancerErin Grothey, Edward Chu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
The role of thymidylate synthase as a molecular biomarkerAntontello DiPaolo, Edward Chu
Clinical Colorectal Cancer|December 17, 2002
Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instabilityLori Johnson, Edward Chu
Clinical Colorectal Cancer|June 15, 2015
Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon CancerAmy Soni, Edward Chu
Clinical Colorectal Cancer|November 27, 2002
Thymidylate Synthase Pharmacogenetics in Colorectal CancerM Sitki Copur, Edward Chu
The New England Journal of Medicine|January 19, 2007
Expanding priorities--confronting chronic disease in countries with low incomeGerard F Anderson, Edward Chu
Oncology (Williston Park, N.Y.)|June 2, 2006
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancersEverett E Vokes, Edward Chu
Oncology (Williston Park, N.Y.)|October 19, 2013
Personalized medicine in the adjuvant chemotherapy of stage II colon cancer--are we there yet?James J Lee, Edward Chu
Clinical Colorectal Cancer|March 1, 2017
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102)James J Lee, Edward Chu
Silence|January 21, 2011
Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitorsJohn C Schmitz, Edward Chu
Pageof 22